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Jefferson researcher Susan Lanza-
Jacoby, PhD, has been awarded 
a two-year grant by the National 
Institutes of Health (NIH) National 
Cancer Institute (NCI) to study the use 
of energy restriction mimetics to slow 
the progression of pancreatic cancer, 
reduce the incidence of pancreatic 
ductal adenocarcinoma and improve 
the survival rate. Dr. Jacoby formally 
initiated the project in September 
with Jonathan Brody, PhD, Director 
of Surgical Research and Co-director 
of the Jefferson Pancreas, Biliary and 
Related Cancer Center, and Jordan 
Winter, MD, FACS, Associate Professor, 
Sidney Kimmel Medical College at 
Thomas Jefferson University.
As Dr. Jacoby explains, cancer cells 
require a lot of glucose, or energy, 
to grow. Energy restriction mimetics 
is the process of limiting glucose to 
hinder cancer cell growth. In one of 
her previous studies, Dr. Jacoby found 
that cutting the caloric intake of mice 
by 25 percent reduced the number 
of animals who developed pancreatic 
cancer. For this new study, the team 
will test whether and to what extent a 
new compound, known as CG5, has 
the same effect. They are collaborating 
with the Ohio State University 
medicinal chemist, Dr. Ching-shih 
Chen, who developed the compound. 
While Jefferson’s is the first study to 
focus on CG5 for pancreatic cancer, 
previous studies have found that the 
compound inhibits the growth of 
colorectal and prostate cancer cells  
in mice.
“By inhibiting glucose metabolism, the 
compound acts, in a sense, like food 
or calorie restriction,” she says. “More 
specifically, CG5 inhibits the glucose 
transporter 1 protein, or GLUT1, which 
is necessary for glucose to get in the 
cell and be broken down into energy. 
The hope is that by inhibiting GLUT1, 
CG5 will ‘starve’ pancreatic tumors.”
This early-stage study will use 
transgenic mice in which every cell 
contains additional foreign DNA. 
This extra DNA enables researchers 
to study gene function or regulation 
and to model human diseases. 
Researchers will be analyzing whether 
and how much the compound 
inhibits carbohydrate metabolism and 
transport and utilization of glucose.
“We will see if we can inhibit the 
growth of what we call precursor can-
cerous lesions – advanced lesions in 
the pancreas that progress to pancre-
atic cancer,” Dr. Brody explains. “We’ll 
also be exploring how the compound 
affects the RNA binding protein, HuR, 
which we’ve been studying in our  
laboratory for a number of years. 
“In other studies, we’ve found that 
inhibiting HuR makes pancreatic 
cancer cells more sensitive to 
chemotherapy. We hypothesize 
that the CG5 compound may also 
inhibit HuR, thereby yielding better 
chemotherapy outcomes.”
Dr. Jacoby emphasizes that this is a 
very early-stage, mouse-model study, 
and it will take extensive research, 
including additional animal studies and 
a toxicity profile, to determine whether 
or not the CG5 compound can be 
safely used in humans. 
“It’s too soon to translate this for 
humans,” she notes. “Ultimately, 
though, the goal is to develop a drug 
that will alter metabolism to reduce 
the incidence and progression of 
pancreatic cancer – without requiring 
people to slash their caloric intake.”
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When Dr. Yeo left Johns Hopkins in October 
of 2005 to lead the Department of Surgery at 
Jefferson, he had big plans. Over the last ten 
years, the improvements have been dramatic 
across the board thanks to the support and 
contributions of five faculty members he 
selected to serve as vice chairs: 
Jonathan Brody, PhD, Vice Chair for 
Research, supervises and facilitates 
research activities in the Department. To 
support and publicize research initiatives, 
Dr. Brody manages a pilot grant program 
for the surgical faculty, a research seminar 
series, and a bi-annual resident research 
symposium. He works with other faculty 
to strengthen the research infrastructure, 
encourage faculty interests, increase 
investigator initiated clinical trials, expand  
the departmental grant portfolio, and 
establish a clinically useful biobank. 
Ernest Rosato, MD, Vice Chair for Clinical 
Affairs, is responsible for supervising 
many elements within the clinical domain 
including faculty roles, the maintenance 
of surgical outcomes, safety and volume. 
Dr. Rosato works closely with Dr. Yeo to 
develop strategies for clinical growth, faculty 
recruitment and retention, and program 
development within the Department and 
across Jefferson Health.
Karen Chojnacki, MD, Vice Chair for 
Education, is responsible for facilitating 
the educational mission of the Department, 
including overseeing the educational 
program for 40 surgical residents. In her role 
as Program Director, Dr. Chojnacki develops 
the resident lecture series, implements 
rotation and call schedules, manages 
resident recruitment, and maintains program 
compliance with the ACGME surgical 
residency requirements. Dr. Chojnacki and 
her education team work continuously to 
maintain the surgical residency’s status as 
a top tier program. In conjunction with the 
Dean’s office, she facilitates educational 
opportunities for faculty development 
including seminars and workshops on 
teaching methods.
Scott Cowan, MD, Vice Chair for Quality, is 
responsible for overseeing the development, 
implementation and tracking of quality and 
safety initiatives within the Department. 
As Surgeon Champion for the American 
College of Surgeons National Surgical 
Quality Improvement Program (ACS 
NSQIP®) at Jefferson and Vice President of 
the Pennsylvania NSQIP Consortium, Dr. 
Cowan is establishing Jefferson as a leader 
in promoting surgical quality and safety. The 
Department’s new Quality Based Initiative in 
Resident Training (QBIRT) program (led by 
surgical residents with Dr. Cowan’s guidance) 
has already demonstrated a direct and 
significant positive impact on patient care.
Francesco Palazzo, MD, Vice Chair at 
Methodist, is responsible for all professional, 
administrative, and research activities within 
the Department of Surgery at Methodist 
Hospital in South Philadelphia. Dr. Palazzo 
continually assesses performance and elicits 
improvements to the care and services 
provided at Methodist. Under his leadership, 
two Methodist “white papers” have been 
completed. Dr. Palazzo also teaches third 
and fourth year students from Sidney 
Kimmel Medical College and Jefferson 
surgery residents during their Methodist 
Hospital rotation. 
In the Curtis Building laboratories, Drs. Jordan Winter, Jonathan Brody, and Suzan Lanza-Jacoby join forces to 
disrupt the energy supply of pancreatic cancer cells.
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